Express Scripts settles drug-switching claims; Taro Pharma terminates Sun merger deal; and much more

> Takeda's quest to expand in the U.S. market--and off-set expiring patents on big drugs--continues. The Japanese company announced today a $1 billion alliance with RNAi company Alnylam. Buyout report

> Pharmacy-benefits manager Express Scripts agreed to pay $9.5 million to settle allegations that it asked doctors to switch drugs primarily so it could get bigger rebates from pharmaceutical companies. Report

> India's Sun Pharmaceuticals said generics maker Taro Pharma has terminated its $454 million merger agreement. Report

> European regulators said Sanofi-Aventis and Bristol-Myers Squibb withdrew their application for a drug that combines the blockbuster anti-clotting med Plavix with aspirin. Report

> AstraZeneca sued Barr Pharmaceuticals to prevent it from selling a generic version of the drug Entocort EC, used to treat Crohn’s disease. Report

> GlaxoSmithKline Consumer Healthcare named Roger Scarlett-Smith president of its North American operations; Scarlett-Smith, 48, previously was head of GlaxoSmithKline's Consumer Healthcare business in the United Kingdom. Report

> Dr Reddy's Laboratories,  the Indian generic company seeking to sell copies of AstraZeneca heartburn drug Nexium, said its patent litigation with the Anglo-Swedish drugmaker is continuing and it is considering options to speed up its resolution. Report

> Sanofi-Aventis said it's taking legal action in Germany against a possible generic competitor to its Plavix blood thinning drug, after the generic version was registered with German federal drug regulators. Report

> San Diego-based Favrille has halted development of Specifid, a treatment for follicular B-cell non-Hodgkin's lymphoma. Favrille report

> Emergent BioSolutions has inked a deal to acquire the Protein Sciences Corporation assets for up to $75 million. Report

> Struggling Discovery Labs signed a three year, $60 million financing deal with Kingsbridge Capital, a U.K.-based investment group. Discovery report

> Canada's Migenix is cutting its staff in an effort to preserve cash. The company, which is developing the anti-infective drug Omigard, cut six workers, reduced its CEO's salary and downsized its board of directors as it awaits results from a Phase III trial of the drug. Migenix report

And Finally... Media coverage of new drugs often fails to mention potential side effects and almost always leaves out treatment costs. Report

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

Pfizer terminated a slew of trial cohorts testing Bavencio in combination with its own experimental drugs, as well as one monotherapy trial.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.